Respiratory Updates
🟢 To stay up-to-date on pharmacotherapy and other aspects of respiratory diseases🫁 🟢 Thoracic Research Center🔬 🟢 Tehran University of Medical Sciences🎓
Show more📈 Analytical overview of Telegram channel Respiratory Updates
Channel Respiratory Updates (@respiratoryupdates) in the English language segment is an active participant. Currently, the community unites 19 592 subscribers, ranking 1 177 in the Medicine category and 17 234 in the Iran region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 19 592 subscribers.
According to the latest data from 06 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 492 over the last 30 days and by 10 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 21.25%. Within the first 24 hours after publication, content typically collects 5.14% reactions from the total number of subscribers.
- Post reach: On average, each post receives 4 162 views. Within the first day, a publication typically gains 1 007 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 11.
- Thematic interests: Content is focused on key topics such as patient, guideline, edit, reader, society.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“🟢 To stay up-to-date on pharmacotherapy and other aspects of respiratory diseases🫁
🟢 Thoracic Research Center🔬
🟢 Tehran University of Medical Sciences🎓”
Thanks to the high frequency of updates (latest data received on 07 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
Source: Journal of Allergy and Clinical Immunology: In PracticeTopic: High-dose inhaled steroids after severe asthma flare show no added benefit In a large U.S. retrospective cohort study, stepping up to high-dose inhaled corticosteroids (ICS) after a severe asthma exacerbation did not reduce future exacerbation risk. Among patients on medium-dose ICS, escalation to high-dose was associated with higher annualized exacerbation rates and increased likelihood of another flare. Similar lack of benefit was seen when escalating from low- to high-dose ICS. Findings suggest alternative strategies may be preferable to routine high-dose ICS escalation after exacerbations. Link: https://pubmed.ncbi.nlm.nih.gov/41167528/ @HakimApps_Guideline
